Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company ProRetina Therapeutics S.L.
DescriptionSustained release formulation of recombinant human proinsulin
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationRetinitis
Indication DetailsTreat retinitis pigmentosa (RP)
Regulatory Designation EU - Orphan Drug (Treat retinitis pigmentosa (RP))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today